Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total transaction of $500,310.00. Following the transaction, the insider owned 130,205 shares in the company, valued at approximately $21,714,287.85. This represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, June 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $157.07, for a total value of $471,210.00.
• On Thursday, May 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $150.12, for a total transaction of $450,360.00.
• On Monday, April 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The shares were sold at an average price of $152.18, for a total transaction of $335,709.08.

Natera Stock Down 0.0%

Shares of NASDAQ:NTRA traded down $0.07 during trading on Friday, hitting $161.50. The stock had a trading volume of 468,868 shares, compared to its average volume of 1,422,668. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The stock has a 50-day simple moving average of $160.18 and a two-hundred day simple moving average of $158.47. The stock has a market capitalization of $22.05 billion, a price-to-earnings ratio of -109.86 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same quarter in the prior year, the business earned ($0.56) earnings per share. The business's quarterly revenue was up 36.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. UBS Group lifted their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Royal Bank Of Canada started coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. Piper Sandler boosted their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Barclays upped their target price on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. Fulton Bank N.A. lifted its holdings in shares of Natera by 2.0% in the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock valued at $516,000 after buying an additional 71 shares during the period. Compound Planning Inc. raised its position in Natera by 4.2% during the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock valued at $271,000 after acquiring an additional 78 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock valued at $766,000 after acquiring an additional 81 shares during the period. Earned Wealth Advisors LLC boosted its position in Natera by 5.0% in the 1st quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock worth $246,000 after purchasing an additional 82 shares in the last quarter. Finally, Bridges Investment Management Inc. grew its stake in shares of Natera by 5.5% during the 1st quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock worth $237,000 after purchasing an additional 87 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.